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Abstract
Background Depression is common in haemodialysis (HD)
patients and associated with poor outcomes.
Purpose To evaluate whether depression symptoms predict
survival and transplantation in a large sample of haemodialysis
patients using cause-specific survival models.
Methods Survival data was collected between April 2013 and
November 2015, as part of the screening phase of a
multicentre randomised placebo-controlled trial of sertraline
in HD patients. Depression was measured using the Beck
Depression Inventory-II (BDI-II) and the Patient Health
Questionnaire-9 (PHQ-9). Demographic and clinical data
were collected via a self-report questionnaire and medical re-
cords. Competing risk survival analysis involved cause-
specific and subdistribution hazard survival models. All
models were adjusted for appropriate covariates including co-
morbidity and C-reactive protein (CRP) in a subanalysis.
Results Of 707 cases available for analysis, there were 148
deaths. The mean survival time was 787.5 days. Cumulative
survival at 12 months was 88.5%. During the study follow-up
period, there were 92 transplants. The cumulative transplant
event rate at 12 months was 7.8%. In separate adjusted
models, depression symptoms predicted mortality (BDI-II
HR = 1.03 95% CI 1.01, 1.04; PHQ-9 HR = 1.04 95% CI
1.01, 1.06). With respect to screening cut-off scores, a PHQ-
9 ≥ 10 was associated with mortality (HR = 1.51 95%CI 1.01,
2.19) but not a BDI-II ≥ 16. Depression symptoms were not
associated with time to transplantation in either cause-specific
or subdistribution model.
Conclusions Consistent with past findings in HD patients,
depression symptoms predicted survival but were not associ-
ated with kidney transplantation. Suitable treatments for de-
pression need further evaluation, and their impact upon qual-
ity of life and clinical outcomes determined.
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Introduction
Depression is a common comorbidity experienced across the
spectrum of advanced kidney disease, particularly in End-
Stage Kidney Failure (ESKF). Estimates of depression, as
determined by cut-off scores from validated screening tools,
suggest that approximately 39% of dialysis patients are de-
pressed [1]. This compares with around 23% when using di-
agnostic interviews [1]. Not only is depression prevalent but it
also contributes to a variety of poor outcomes, including in-
creased hospitalisation and mortality amongst dialysis pa-
tients, a finding that has been well-documented within the
literature [2–7]. For example, a recent meta-analysis reports
that the presence of depressive symptoms in dialysis patients
is associated with a 50% increase in the risk of mortality
(HR = 1.51, 95% confidence interval 1.35–1.69) [4]. The
authors of this review conclude that there is considerable het-
erogeneity regarding the measurement of depression between
studies, although overall, depression symptoms appear to be
independent predictors of mortality. What is not clear from
this review, however, was the number of studies which con-
sidered the presence of competing risks, a methodological
issue which is addressed in the present study.
To elaborate, the examination of outcomes in ESKF is com-
plicated by the presence of competing risks [8], which can
include mortality, transplantation events and recovering renal
function. A competing risk refers to “an event that either hin-
ders the observation of the event of interest or modifies the
chance that this event occurs” [8]. Thus, in the context of ex-
amining survival in dialysis patients, transplantation is a com-
peting event, since after transplantation the trajectory of health
outcomes and risk of death is significantly altered. We are not
aware of any previous studies examining the association be-
tween depression symptoms and survival in dialysis patients
that have suitably handled the issue of competing risks.
In addition to considering the competing risks faced when
evaluating outcomes in dialysis patients, the role of depression
as a predictor of transplantation has not been extensively stud-
ied [9]. Past work has shown that depression is associated with
reduced odds of being on the kidney transplant waiting list but
not a predictor of transplantation in those already on the
waiting list [9]. Since depression symptoms are amongst the
most common of extra renal comorbidities, it is important to
observe whether they are associated with transplantation, after
adjustment for potential confounding factors such as age and
physical comorbidities. Furthermore, since increased survival
is associated with transplantation compared with dialysis [10],
depression might be associated with survival in ESKF due to
the reduced likelihood of receiving a kidney transplant.
Currently, there is not enough data to examine the relationship
between these outcomes.
The aims of this study were two-fold: (1) observe the
causal-specific association between depression severity with
mortality and transplant outcomes using two depression
screening tools and (2) observe these relationships using
prevalidated screening cut-off scores, indicating significant
depressive symptomatology.
Methods
Design This prospective survival analysis utilised depression
screening data (n = 709) to select patients into a multicentre
placebo-controlled feasibility randomised control trial (RCT)
of sertraline in HD patients with mild to moderate Major
Depressive Disorder [11]. The full RCT protocol (trial regis-
tration number: ISRCTN06146268) [11] and the outcome pa-
per [12] have been published elsewhere.
Patients were first screened for depression using two vali-
dated symptom severity measures (n = 709). Following screen-
ing of 709 HD patients, 231 patients (32.3%) had a Beck
Depression Inventory-II (BDI-II) score of 16 or above. Sixty-
three patients were eligible for further study and consented to
be seen by the study psychiatrist, of which 37 (58.7%) were
diagnosed with major depressive disorder (MDD). Thirty pa-
tients consented to be randomised, with 15 patients being
randomised to sertraline and 15 to placebo groups. Patients
were follow-up for 6 months as part of the original RCT.
The study reported here observed mortality and transplanta-
tion outcomes (i.e. receipt of a kidney transplant) from the point
of depression screening (earliest entry 1st April 2013) until 1st
November 2015 (end of follow-up). The screening period lasted
until the end of October 2014. The date of completion of baseline
screening data served as time zero in the survivalmodels reported
here. Outcome data was collected by medical records review,
conducted by local study nephrologists. The median follow-up
time was 579 days (interquartile range = 364).
Patients Patients were selected from the prevalent adult HD
patients treated in five UK dialysis centres (see Friedli et al. [11]
for full details of the original RCT). Adult ESKF patients who
had been on HD for at least 3 months and who could speak and
read English well enough to complete the questionnaires were
eligible to be screened for depression. Patients provided con-
sent for the research team to access their medical notes over the
study duration. We also sought and had approved an ethics
amendment to allow us to collect this outcome data.
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Depression Measures Depression symptoms were measured
using two validated screening tools: (1) Beck Depression
Inventory-II (BDI-II) [13] and (2) Patient Health
Questionnaire-9 (PHQ-9) [14]. Both measures have shown
validity for use within dialysis patients [15–17]. As well as
continuous total scores, cut-off scores were also used to indi-
cate significant depressive symptoms (PHQ-9 score ≥ 10 and a
BDI-II ≥ 16) [15, 16]. In the present study, both the BDI-II and
PHQ-9 total scores had high internal reliabilities (α = 0.93 and
α = 0.88, respectively).
Clinical and Demographic Factors Demographic informa-
tion was collected through a self-report questionnaire.
Routinely collected clinical data was recorded from medical
records, which included the comorbidities (presence of diabe-
tes, heart disease, stroke, cancer, limb amputation, liver dis-
ease, lung disease), dialysis vintage (length of time on dialy-
sis), haemoglobin (g/L), serum albumin (g/L), dialysis treat-
ment adequacy (Kt/V) and dry weight (kg). C-reactive protein
(CRP, mg/L), a marker of inflammation, was available in a
subset of the sample (n = 396) since it is not routinely
measured.
Statistical Methods
All analysis was conducted in STATA 11.2. Separate cause-
specific hazard survival models, using Cox regression, were
evaluated for both survival and transplantation outcomes.
Patients were censored for the alternative (competing) event.
In addition, censorship occurred in relation to lost to follow-
up, switching dialysis modality and recovering renal function.
Using this approach, Hazard Ratios (HRs) are interpreted as
“among those patients who did not (yet) experience the event
of interest or competing event” (see Noordzij et al. [8]). For
example, if age predicted survival with a HR of 1.05, it would
be interpreted as “in those who did not experience the event of
interest (death) or a competing event (transplantation), a year
increase in age is associated with a 5% increase in the hazard
of death”.
The analysis was repeated using subdistribution hazard
models using the approach proposed by Fine and Gray [18].
This analysis provides estimates of the probability of an event
(e.g. mortality) after considering a competing event (e.g. trans-
plantation). Subdistribution Hazard Ratios (SHRs) that result
from this method cannot be interpreted as an HR. Rather, SHRs
represent the ratio in a “non-existing population including those
who experience the competing event” [8]. Put another way, a
SHR for survival reflects the “mortality rate ratio among pa-
tients who are alive or have been transplanted before” [8].
In adjusted analysis, covariates were selected from clinical
and demographic variables that showed univariate associa-
tions with the two outcomes of interest. For survival, the
following covariates were adjusted for age, ethnicity (white
vs. non-white), heart disease (present vs. not present), ampu-
tation of limbs (yes vs. no), diabetes (yes vs. no), haemoglobin
(g/L), serum albumin (g/L), dialysis adequacy, dry weight (kg)
and dialysis centre (dummy coded). With regard to transplan-
tation, the following covariates were adjusted for age, ethnic-
ity, heart disease, diabetes, haemoglobin, serum albumin,
number of past kidney transplants and dialysis centre.
In all sets of analysis, the impact of depression symptoms
upon the outcomes was evaluated in separate adjusted models
that considered depression severity as a continuous score (ei-
ther the PHQ-9 or BDI-II total score) or a measure-specific
cut-off score (either a PHQ-9 score ≥ 10 or BDI-II ≥ 16).
These cut-off scores were entered as a binary independent
variable (i.e. depressed yes vs. no).
CRP was available in a subsample, since it is not routinely
measured. Since CRP is associated with survival in dialysis
patients [19, 20], we rerun the models in this subsample con-
trolling for the respective covariates above and CRP (>5 mg/
L). In addition, we also explored the potential interaction be-
tween depression and ethnicity (white vs. non-white) upon
survival since past evidence has suggested a moderated effect
in kidney disease patients [21].
We report statistical significance using the standard
p < 0.05 criteria. In addition, given that for each analytical
method and outcome we treated depression symptoms using
four methods, an adjusted p value cut-off (0.013) is also
reported.
Results
Patient Characteristics
A summary of demographic and clinical characteristics is
shown in Table 1. The majority of the sample was male
(63.3%), and the average age was 64.1 (16.4) years. The
median dialysis vintage was 33 months (interquartile
range = 59). Mean depression scores at baseline were
13.5 (s.d. = 11.4) and 6.9 (s.d. = 6.2) for the BDI-II and
PHQ-9, respectively. A total of 33.2% (95% confidence
interval 30–37) had a BDI-II ≥ 16, and 28.1% (95% con-
fidence interval 25–31) scored ≥10 on the PHQ-9. As
expected, there was a strong association between the pro-
portion of patient meeting both these thresholds (Chi-
square = 375, p < 0.001). Furthermore, both the PHQ-9
and BDI-II total scores correlated highly (r = 0.86,
p < 0.01).
In the subsample where CRP was available (n = 396), 52%
had a CRP > 5mg/L. Comparing those patients with CRP data
and those without revealed no significant differences with
regard to depression scores or the proportion scoring positive-
ly (BDI-II ≥ 16 and PHQ-9 ≥ 10).
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in kidney disease patients [21].
We report statistical significance using the standard
p < 0.05 criteria. In addition, given that for each analytical
method and outcome we treated depression symptoms using
four methods, an adjusted p value cut-off (0.013) is also
reported.
Results
Patient Characteristics
A summary of demographic and clinical characteristics is
shown in Table 1. The majority of the sample was male
(63.3%), and the average age was 64.1 (16.4) years. The
median dialysis vintage was 33 months (interquartile
range = 59). Mean depression scores at baseline were
13.5 (s.d. = 11.4) and 6.9 (s.d. = 6.2) for the BDI-II and
PHQ-9, respectively. A total of 33.2% (95% confidence
interval 30–37) had a BDI-II ≥ 16, and 28.1% (95% con-
fidence interval 25–31) scored ≥10 on the PHQ-9. As
expected, there was a strong association between the pro-
portion of patient meeting both these thresholds (Chi-
square = 375, p < 0.001). Furthermore, both the PHQ-9
and BDI-II total scores correlated highly (r = 0.86,
p < 0.01).
In the subsample where CRP was available (n = 396), 52%
had a CRP > 5mg/L. Comparing those patients with CRP data
and those without revealed no significant differences with
regard to depression scores or the proportion scoring positive-
ly (BDI-II ≥ 16 and PHQ-9 ≥ 10).
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Survival Data and Outcomes
Of 707 cases available for analysis, there were 148 deaths.
The estimated mean survival time was 787.5 days
(s.e. = 10.4). Cumulative survival at 12 months was 88.5%.
During the study follow-up period, there were 92 transplants
(estimated mean survival time was 837.0 days, s.e. = 9.0). The
cumulative transplant event rate at 12 months was 7.8% (by
12months, 7.8% of the sample had received a transplant). The
following censorship events were observed: lost to follow-up
(n = 6), recovered renal function (n = 2) and switched dialysis
modality (n = 1).
Covariate-Adjusted Causal-Specific Hazard Models:
Association of Depression Symptoms upon Mortality
In separate adjusted models, both the PHQ-9 and BDI-II pre-
dicted mortality (Table 2). In those who did not experience the
event of interest (death) or a competing event (transplantation),
a 1-point increase on the BDI-II and PHQ-9 was associated
with a 3 and 4% increase in the hazard of death, respectively.
With respect to screening cut-offs, only the PHQ-9 (≥10) was
significantly associated with mortality (HR = 1.51, Fig. 1). A
BDI ≥ 16 was not significantly associated with mortality
(HR = 1.43, p = 0.055), although the effect size was similar
to that of a PHQ-9 ≥ 10. After applying adjusted p value
criteria, only the effect of the BDI-II and PHQ-9 continuous
scores remained significant (Table 2).
In subanalysis where CRP data was available, both BDI-II
and PHQ-9 scores were associated with survival in adjusted
models (Table 2). These effects were non-significant after ap-
plying adjusted p value criteria. Neither depression cut-off
scores were associated with survival. All models were rerun
examining the interaction (moderation) between depression
and ethnicity upon survival. There was no significant interac-
tion between depression (measured both as a continuous and
cut-off score for the respective tools) and ethnicity upon mor-
tality in either unadjusted or adjusted model (including CRP-
adjusted subanalysis).
Covariate-Adjusted Causal-Specific Hazard Models:
Association of Depression Symptoms
upon Transplantation
Depression symptoms, treated as either a continuous total
score or cut-off score, were not associated with transplantation
events (see Fig. 2 for PHQ-9 cut-off score hazard functions).
In the subanalysis that also controlled for CRP, the same null
effects were observed (Table 2).
Completing Risk Subdistribution Hazard Models
In addition to the causal-specific models, risk subdistribution
hazard models were also evaluated for both mortality and
transplantation (Table 2). For mortality, depression symptoms,
treated as either a continuous total score or cut-off score, were
associated with a greater cumulative incidence of death. In
these models, the SHRs reflect the mortality ratio amongst
patients who are alive or have been transplanted. However,
after applying adjusted p value criteria, only the SHRs for the
BDI-II and PHQ-9 continuous scores remained significant
(Table 2). Similar to the cause-specific models, there were
no associations between depression symptoms and kidney
transplantation.
Discussion
The aims of this paper were to examine the causal-specific
associations between depression symptoms with both survival
and kidney transplantation outcomes. We are not aware of any
similar studies examining depression and mortality in dialysis
patients where the competing event of transplantation has
been considered.
Firstly, we found that approximately one in three patients
had significant depressive symptoms as indicated by screen-
ing cut-offs of the BDI-II and PHQ-9. These results are in line
Table 1 Summary of patient characteristics
Variable Statistic
Age (mean, s.d.) 64.1 (16.4)
Gender (male, %) 63.3
Ethnicity (white, %) 69.0
Dialysis vintage (median, IQR) 33 (59)
Number of past transplants
None 84%
1 14%
2 2%
Heart disease (%) 31.7
Diabetes (%) 33.3
Cancer (%) 10.6
Liver disease (%) 2.4
Lung disease (%) 6.4
Amputation of limbs (%) 3.2
Stroke (%) 8.0
Haemoglobin (g/L) (mean, s.d.) 11.1 (1.2)
Serum albumin (g/L) (mean, s.d.) 37.4 (4.4)
Dry weight (kg) (mean, s.d.) 75.5 (18.3)
CRPa (>5 mg/L, %) 52%
Kt/V (mean, s.d.) 1.4 (0.3)
a Subsample (n = 396)
IQR interquartile range
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with previous research [1] and further highlight that depres-
sive symptoms are commonly experienced in dialysis patients.
Our findings here corroborate with past research showing
that depression predicts all-cause mortality amongst dialysis
patients [4]. However, unlike our past work in incident dialy-
sis patients [2], we failed to show that a BDI cut-off score ≥ 16
was significantly associated with survival, although a PHQ-9
score ≥ 10 was associated with an increased risk of death with
a comparable effect size observed in a recent meta-analysis
[4]. After adjusted p value criteria were applied however, only
the effect of the BDI-II and PHQ-9 continuous scores
remained significant. It is possible that BDI-II and PHQ-9
cut-offs were not significant due to loss of information that
occurs when dichotomizing the continuous predictor.
A strength of our study is the consideration of the compet-
ing influence of transplantation by using adjusted cause-
specific survival models. We found that depressive symptoms,
as measured by two validated screening tools (BDI-II and
PHQ-9), were not predictive of transplantation events, null
findings that remained in subdistribution analysis.With regard
Table 2 The association between
depression with mortality and
transplantation outcomes:
adjusted cause-specific and
subdistribution models
Cause-specific models
(HRs and 95% CI)
Subdistribution competing risks model
(SHRs and 95% CI)
Mortalitya Transplantationb Mortalitya Transplantationb
Full sample (n=707)
BDI 1.03 (1.01, 1.04)**[*] 0.98 (0.96, 1.01) 1.03 (1.01, 1.04)**[*] 0.98 (0.96, 1.01)
PHQ-9 1.04 (1.01, 1.06)**[*] 0.98 (0.94, 1.02) 1.04 (1.01, 1.06)**[*] 0.97 (0.93, 1.01)
BDI ≥ 16 1.43 (0.99, 2.06) 0.84 (0.54, 1.32) 1.47 (1.02, 2.11)* 0.82 (0.52, 1.29)
PHQ-9 ≥ 10 1.51 (1.04, 2.19)* 0.85 (0.52, 1.38) 1.54 (1.06, 2.24)* 0.83 (0.50, 1.35)
CRP adjusted sub-analysis (n = 396)
BDI 1.03 (1.01, 1.05)* 0.99 (0.96, 1.01) 1.03 (1.01, 1.06)* 0.99 (0.96, 1.01)
PHQ-9 1.04 (1.00, 1.10)* 0.97 (0.93, 1.01) 1.05 (1.01, 1.10)* 0.97 (0.91, 1.62)
BDI ≥ 16 1.54 (0.87, 2.73) 0.77 (0.44, 1.35) 1.61 (0.91, 2.90) 0.76 (0.43, 1.32)
PHQ-9 ≥ 10 1.70 (0.94, 2.90) 0.78 (0.43, 1.40) 1.73 (0.97, 3.11) 0.76 (0.41, 1.40)
aModel adjusted for age, ethnicity (white vs. non-white), heart disease (present vs. not present), amputation of
limbs (yes vs. no), diabetes (yes vs. no), haemoglobin (g/L), serum albumin (g/L), dialysis adequacy, dry weight
(kg) and dialysis centre (dummy coded)
bModel adjusted for age, ethnicity, heart disease, diabetes, haemoglobin, serum albumin, number of past kidney
transplants and dialysis centre
CRP-adjusted models controlled for the relevant covariates listed above in addition to CRP > 5 (binary variable)
HR hazard ratio, SHR subdistribution hazard ratio, CI confidence interval
*p < 0.05; **p < 0.01
[*] indicates significance following adjusted p value cut-off (p < 0.013)
Fig. 1 Adjusted survival plot showing hazard functions for patients with
PHQ < 10 and PHQ-9 ≥ 10
Fig. 2 Adjusted survival (time to transplantation) plot showing hazard
functions for patients with PHQ < 10 and PHQ-9 ≥ 10
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Survival Data and Outcomes
Of 707 cases available for analysis, there were 148 deaths.
The estimated mean survival time was 787.5 days
(s.e. = 10.4). Cumulative survival at 12 months was 88.5%.
During the study follow-up period, there were 92 transplants
(estimated mean survival time was 837.0 days, s.e. = 9.0). The
cumulative transplant event rate at 12 months was 7.8% (by
12months, 7.8% of the sample had received a transplant). The
following censorship events were observed: lost to follow-up
(n = 6), recovered renal function (n = 2) and switched dialysis
modality (n = 1).
Covariate-Adjusted Causal-Specific Hazard Models:
Association of Depression Symptoms upon Mortality
In separate adjusted models, both the PHQ-9 and BDI-II pre-
dicted mortality (Table 2). In those who did not experience the
event of interest (death) or a competing event (transplantation),
a 1-point increase on the BDI-II and PHQ-9 was associated
with a 3 and 4% increase in the hazard of death, respectively.
With respect to screening cut-offs, only the PHQ-9 (≥10) was
significantly associated with mortality (HR = 1.51, Fig. 1). A
BDI ≥ 16 was not significantly associated with mortality
(HR = 1.43, p = 0.055), although the effect size was similar
to that of a PHQ-9 ≥ 10. After applying adjusted p value
criteria, only the effect of the BDI-II and PHQ-9 continuous
scores remained significant (Table 2).
In subanalysis where CRP data was available, both BDI-II
and PHQ-9 scores were associated with survival in adjusted
models (Table 2). These effects were non-significant after ap-
plying adjusted p value criteria. Neither depression cut-off
scores were associated with survival. All models were rerun
examining the interaction (moderation) between depression
and ethnicity upon survival. There was no significant interac-
tion between depression (measured both as a continuous and
cut-off score for the respective tools) and ethnicity upon mor-
tality in either unadjusted or adjusted model (including CRP-
adjusted subanalysis).
Covariate-Adjusted Causal-Specific Hazard Models:
Association of Depression Symptoms
upon Transplantation
Depression symptoms, treated as either a continuous total
score or cut-off score, were not associated with transplantation
events (see Fig. 2 for PHQ-9 cut-off score hazard functions).
In the subanalysis that also controlled for CRP, the same null
effects were observed (Table 2).
Completing Risk Subdistribution Hazard Models
In addition to the causal-specific models, risk subdistribution
hazard models were also evaluated for both mortality and
transplantation (Table 2). For mortality, depression symptoms,
treated as either a continuous total score or cut-off score, were
associated with a greater cumulative incidence of death. In
these models, the SHRs reflect the mortality ratio amongst
patients who are alive or have been transplanted. However,
after applying adjusted p value criteria, only the SHRs for the
BDI-II and PHQ-9 continuous scores remained significant
(Table 2). Similar to the cause-specific models, there were
no associations between depression symptoms and kidney
transplantation.
Discussion
The aims of this paper were to examine the causal-specific
associations between depression symptoms with both survival
and kidney transplantation outcomes. We are not aware of any
similar studies examining depression and mortality in dialysis
patients where the competing event of transplantation has
been considered.
Firstly, we found that approximately one in three patients
had significant depressive symptoms as indicated by screen-
ing cut-offs of the BDI-II and PHQ-9. These results are in line
Table 1 Summary of patient characteristics
Variable Statistic
Age (mean, s.d.) 64.1 (16.4)
Gender (male, %) 63.3
Ethnicity (white, %) 69.0
Dialysis vintage (median, IQR) 33 (59)
Number of past transplants
None 84%
1 14%
2 2%
Heart disease (%) 31.7
Diabetes (%) 33.3
Cancer (%) 10.6
Liver disease (%) 2.4
Lung disease (%) 6.4
Amputation of limbs (%) 3.2
Stroke (%) 8.0
Haemoglobin (g/L) (mean, s.d.) 11.1 (1.2)
Serum albumin (g/L) (mean, s.d.) 37.4 (4.4)
Dry weight (kg) (mean, s.d.) 75.5 (18.3)
CRPa (>5 mg/L, %) 52%
Kt/V (mean, s.d.) 1.4 (0.3)
a Subsample (n = 396)
IQR interquartile range
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with previous research [1] and further highlight that depres-
sive symptoms are commonly experienced in dialysis patients.
Our findings here corroborate with past research showing
that depression predicts all-cause mortality amongst dialysis
patients [4]. However, unlike our past work in incident dialy-
sis patients [2], we failed to show that a BDI cut-off score ≥ 16
was significantly associated with survival, although a PHQ-9
score ≥ 10 was associated with an increased risk of death with
a comparable effect size observed in a recent meta-analysis
[4]. After adjusted p value criteria were applied however, only
the effect of the BDI-II and PHQ-9 continuous scores
remained significant. It is possible that BDI-II and PHQ-9
cut-offs were not significant due to loss of information that
occurs when dichotomizing the continuous predictor.
A strength of our study is the consideration of the compet-
ing influence of transplantation by using adjusted cause-
specific survival models. We found that depressive symptoms,
as measured by two validated screening tools (BDI-II and
PHQ-9), were not predictive of transplantation events, null
findings that remained in subdistribution analysis.With regard
Table 2 The association between
depression with mortality and
transplantation outcomes:
adjusted cause-specific and
subdistribution models
Cause-specific models
(HRs and 95% CI)
Subdistribution competing risks model
(SHRs and 95% CI)
Mortalitya Transplantationb Mortalitya Transplantationb
Full sample (n=707)
BDI 1.03 (1.01, 1.04)**[*] 0.98 (0.96, 1.01) 1.03 (1.01, 1.04)**[*] 0.98 (0.96, 1.01)
PHQ-9 1.04 (1.01, 1.06)**[*] 0.98 (0.94, 1.02) 1.04 (1.01, 1.06)**[*] 0.97 (0.93, 1.01)
BDI ≥ 16 1.43 (0.99, 2.06) 0.84 (0.54, 1.32) 1.47 (1.02, 2.11)* 0.82 (0.52, 1.29)
PHQ-9 ≥ 10 1.51 (1.04, 2.19)* 0.85 (0.52, 1.38) 1.54 (1.06, 2.24)* 0.83 (0.50, 1.35)
CRP adjusted sub-analysis (n = 396)
BDI 1.03 (1.01, 1.05)* 0.99 (0.96, 1.01) 1.03 (1.01, 1.06)* 0.99 (0.96, 1.01)
PHQ-9 1.04 (1.00, 1.10)* 0.97 (0.93, 1.01) 1.05 (1.01, 1.10)* 0.97 (0.91, 1.62)
BDI ≥ 16 1.54 (0.87, 2.73) 0.77 (0.44, 1.35) 1.61 (0.91, 2.90) 0.76 (0.43, 1.32)
PHQ-9 ≥ 10 1.70 (0.94, 2.90) 0.78 (0.43, 1.40) 1.73 (0.97, 3.11) 0.76 (0.41, 1.40)
aModel adjusted for age, ethnicity (white vs. non-white), heart disease (present vs. not present), amputation of
limbs (yes vs. no), diabetes (yes vs. no), haemoglobin (g/L), serum albumin (g/L), dialysis adequacy, dry weight
(kg) and dialysis centre (dummy coded)
bModel adjusted for age, ethnicity, heart disease, diabetes, haemoglobin, serum albumin, number of past kidney
transplants and dialysis centre
CRP-adjusted models controlled for the relevant covariates listed above in addition to CRP > 5 (binary variable)
HR hazard ratio, SHR subdistribution hazard ratio, CI confidence interval
*p < 0.05; **p < 0.01
[*] indicates significance following adjusted p value cut-off (p < 0.013)
Fig. 1 Adjusted survival plot showing hazard functions for patients with
PHQ < 10 and PHQ-9 ≥ 10
Fig. 2 Adjusted survival (time to transplantation) plot showing hazard
functions for patients with PHQ < 10 and PHQ-9 ≥ 10
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to mortality, in subdistribution models, depression symptoms
remained a predictor of survival when the competing event of
transplantation was considered, an effect which was main-
tained after p value adjustment.
In a subsample where CRP was available, the results
remained similar although only continuous depression symp-
tom scores were predictive of mortality. However, these ef-
fects become non-significant after applying adjusted p value
criteria. Controlling for CRP did appear to attenuate the effect
of depression as defined by a PHQ-9 cut-off score of ≥10.
Depression screening cut-off scores indicate greater levels of
depressive affect, which in some cases (but not all) will cor-
respond to clinical depression. CRP and depression have been
the focus of past studies, with some showing a positive asso-
ciation between depression and inflammation [22, 23]. This
association might explain the observed attenuation of the ef-
fect between depression and survival with respect to the PHQ-
9 cut-off score, although it should be acknowledged that the
association between inflammation and depression in ESKF is
mixed [24, 25].
The mechanisms through which depression predicts sur-
vival remain elusive, although several candidate pathways
exist [26]. Depression may impact survival by allostatic dys-
regulation [26], a potential pathway that implicates the rela-
tionship between malnutrition, inflammation and atheroscle-
rosis (MIA syndrome). There are close associations between
these factors in ESKF [26–28] and some preliminary evidence
that depression could be involved in MIA syndrome [29].
Depression might also be associated with mortality via be-
havioural mechanisms, most notably treatment non-adherence
[26, 30, 31]. Depression is associated with non-adherence to
various aspects of the ESKF regimen [31], and non-adherence
is predictive of poor outcomes including survival [31, 32].
There is evidence that depression symptoms are associated
with increased hospitalisation [5] and health care use [33] in
dialysis patients. Although speculative, such increased health
care use might be the result of greater non-adherence and
poorer self-management in those with depression.
With regard to transplantation, the finding that self-
reported depression is not associated with kidney transplanta-
tion events is of importance and relevance to clinical practice.
Comorbidities are common in dialysis patients and associated
with both the eligibility and time to transplantation. Since
depression is a prevalent extra renal comorbidity it might be
expected to have some association with transplantation events.
However, in cause-specific and subdistribution models, there
was no evidence of an association between transplant events
and depression. It is reassuring that depression symptoms do
not differentiate transplant likelihood. However, this is not to
say that depression is not important in the context of trans-
plantation, particularly since depressive symptoms predict
transplant outcomes (i.e. graft failure, for a review see [34]).
Our findings partially support past data, which reports no
association between depression and transplantation within pa-
tients on the transplant waiting list [9]. However, depression
has been found to be associated with the odds of being on the
transplant waiting list [9], with a 5-point increase in depres-
sion score associated with a 9% reduction in the odds of being
on the waiting list. Unfortunately, wait-listing status data was
not available in the current study. However, using competing
risks models, we observed no relationship between depression
and transplantation across our entire sample. This suggests
that the relationship between depression and survival in dial-
ysis patients does not appear to be influenced by fewer trans-
plants in patients with depression and therefore a prolonged
time on dialysis, which is associated with poorer outcomes
compared with kidney transplantation [10].
Strengths of the study include a large sample size, use of
two different validated depression screening tools, very limit-
ed data loss (i.e. lost to follow-up) and causal-specific survival
models. However, our study has some potential limitations to
consider when evaluating the findings. With regard to screen-
ing, both the BDI-II and PHQ-9 contain somatic symptoms
which overlap with other common symptoms associated with
ESKF [35], potentially inflating scores and impacting upon
measurement validity. However, both of these tools have been
shown to compare well to diagnostic criteria, with validated
renal-specific cut-off scores reported in the literature [15]. A
further limitation was our all-cause mortality end-point, which
prevents the evaluation of cause-specific mortality, particular-
ly CVD-related death. Others report an association between
cardiovascular-related mortality and depression in dialysis pa-
tients [7]. A recent study however found that depression was
only predictive of all-cause mortality and not CVD-related
death [3], albeit when using a higher BDI cut-off score
(≥20). Furthermore, due to current complexities of evaluating
depression in non-English-speaking patients [36], our study
was limited to those who could comprehend the measures;
therefore, these findings may not be generalisable to the entire
dialysis population. Others have reported moderated effects
between depression and ethnicity with respect to both renal
disease mortality [21] and all-cause mortality in the general
population [37]. These findings were not replicated here.
However, our reliance on English-speaking patients and our
relatively crude white vs. non-white comparison may have
contributed to this null finding; thus, more research examining
these effects are warranted.
Lastly, the cut-offs used for the BDII-II and PHQ-9, whilst
validated, do not represent a clinical diagnosis of major de-
pressive disorder. Unfortunately, the number of patients who
underwent diagnostic interview for MDD as part of the RCT
(n = 63) was too small to test the association between clinical
depression (MDD) and outcomes.
To conclude, our results support past data showing that
depression symptoms are associated with mortality in ESKF.
Importantly, depressive symptoms do not appear to
ann. behav. med.
differentiate between transplantation events. Efforts to further
understand the mechanisms through which depression symp-
toms influencemortality and evaluate which treatment options
are the most appropriate for ESKF patients require greater
research if outcomes are to be improved.
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to mortality, in subdistribution models, depression symptoms
remained a predictor of survival when the competing event of
transplantation was considered, an effect which was main-
tained after p value adjustment.
In a subsample where CRP was available, the results
remained similar although only continuous depression symp-
tom scores were predictive of mortality. However, these ef-
fects become non-significant after applying adjusted p value
criteria. Controlling for CRP did appear to attenuate the effect
of depression as defined by a PHQ-9 cut-off score of ≥10.
Depression screening cut-off scores indicate greater levels of
depressive affect, which in some cases (but not all) will cor-
respond to clinical depression. CRP and depression have been
the focus of past studies, with some showing a positive asso-
ciation between depression and inflammation [22, 23]. This
association might explain the observed attenuation of the ef-
fect between depression and survival with respect to the PHQ-
9 cut-off score, although it should be acknowledged that the
association between inflammation and depression in ESKF is
mixed [24, 25].
The mechanisms through which depression predicts sur-
vival remain elusive, although several candidate pathways
exist [26]. Depression may impact survival by allostatic dys-
regulation [26], a potential pathway that implicates the rela-
tionship between malnutrition, inflammation and atheroscle-
rosis (MIA syndrome). There are close associations between
these factors in ESKF [26–28] and some preliminary evidence
that depression could be involved in MIA syndrome [29].
Depression might also be associated with mortality via be-
havioural mechanisms, most notably treatment non-adherence
[26, 30, 31]. Depression is associated with non-adherence to
various aspects of the ESKF regimen [31], and non-adherence
is predictive of poor outcomes including survival [31, 32].
There is evidence that depression symptoms are associated
with increased hospitalisation [5] and health care use [33] in
dialysis patients. Although speculative, such increased health
care use might be the result of greater non-adherence and
poorer self-management in those with depression.
With regard to transplantation, the finding that self-
reported depression is not associated with kidney transplanta-
tion events is of importance and relevance to clinical practice.
Comorbidities are common in dialysis patients and associated
with both the eligibility and time to transplantation. Since
depression is a prevalent extra renal comorbidity it might be
expected to have some association with transplantation events.
However, in cause-specific and subdistribution models, there
was no evidence of an association between transplant events
and depression. It is reassuring that depression symptoms do
not differentiate transplant likelihood. However, this is not to
say that depression is not important in the context of trans-
plantation, particularly since depressive symptoms predict
transplant outcomes (i.e. graft failure, for a review see [34]).
Our findings partially support past data, which reports no
association between depression and transplantation within pa-
tients on the transplant waiting list [9]. However, depression
has been found to be associated with the odds of being on the
transplant waiting list [9], with a 5-point increase in depres-
sion score associated with a 9% reduction in the odds of being
on the waiting list. Unfortunately, wait-listing status data was
not available in the current study. However, using competing
risks models, we observed no relationship between depression
and transplantation across our entire sample. This suggests
that the relationship between depression and survival in dial-
ysis patients does not appear to be influenced by fewer trans-
plants in patients with depression and therefore a prolonged
time on dialysis, which is associated with poorer outcomes
compared with kidney transplantation [10].
Strengths of the study include a large sample size, use of
two different validated depression screening tools, very limit-
ed data loss (i.e. lost to follow-up) and causal-specific survival
models. However, our study has some potential limitations to
consider when evaluating the findings. With regard to screen-
ing, both the BDI-II and PHQ-9 contain somatic symptoms
which overlap with other common symptoms associated with
ESKF [35], potentially inflating scores and impacting upon
measurement validity. However, both of these tools have been
shown to compare well to diagnostic criteria, with validated
renal-specific cut-off scores reported in the literature [15]. A
further limitation was our all-cause mortality end-point, which
prevents the evaluation of cause-specific mortality, particular-
ly CVD-related death. Others report an association between
cardiovascular-related mortality and depression in dialysis pa-
tients [7]. A recent study however found that depression was
only predictive of all-cause mortality and not CVD-related
death [3], albeit when using a higher BDI cut-off score
(≥20). Furthermore, due to current complexities of evaluating
depression in non-English-speaking patients [36], our study
was limited to those who could comprehend the measures;
therefore, these findings may not be generalisable to the entire
dialysis population. Others have reported moderated effects
between depression and ethnicity with respect to both renal
disease mortality [21] and all-cause mortality in the general
population [37]. These findings were not replicated here.
However, our reliance on English-speaking patients and our
relatively crude white vs. non-white comparison may have
contributed to this null finding; thus, more research examining
these effects are warranted.
Lastly, the cut-offs used for the BDII-II and PHQ-9, whilst
validated, do not represent a clinical diagnosis of major de-
pressive disorder. Unfortunately, the number of patients who
underwent diagnostic interview for MDD as part of the RCT
(n = 63) was too small to test the association between clinical
depression (MDD) and outcomes.
To conclude, our results support past data showing that
depression symptoms are associated with mortality in ESKF.
Importantly, depressive symptoms do not appear to
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differentiate between transplantation events. Efforts to further
understand the mechanisms through which depression symp-
toms influencemortality and evaluate which treatment options
are the most appropriate for ESKF patients require greater
research if outcomes are to be improved.
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